Rajan Khanna, MD
Internal Medicine · Shreveport, LANPI 1770581225
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $35,389 of the $54,045 with a category attached, or 65.5%. GSK accounts for 62.8% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2024 at $36,202 and has fallen 95.6% since, to $1,604 in 2025. Among internal medicine clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 357 payments — averaging $151.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$34K
- AstraZeneca$5K
- Amgen$3K
- Lilly USA, LLC$1K
- Paratek Pharmaceuticals, Inc.$1K
- Sanofi-aventis U.S. LLC$1K
- plus $8K from 34 others
Across 2 payments — averaging $2400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$5K
What the payments were for
- Consulting fees$35,38965%
- Food & beverage$18,51334%
- Education$1430%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $33,946 |
| AstraZeneca | 72 | $5,002 |
| Amgen | 45 | $2,676 |
| Lilly USA, LLC | 34 | $1,489 |
| Paratek Pharmaceuticals, Inc. | 19 | $1,477 |
| Sanofi-aventis U.S. LLC | 10 | $1,293 |
| Bayer | 15 | $736 |
| Novo Nordisk | 18 | $730 |
| Merck | 14 | $681 |
| AbbVie(2 entities) | 10 | $506 |
| Johnson & Johnson | 8 | $412 |
| Amarin Pharma, Inc. | 3 | $375 |
| Daiichi Sankyo Inc. | 3 | $375 |
| Sumitomo Pharma America, Inc. | 18 | $368 |
| Melinta Therapeutics, LLC | 4 | $346 |
| Astellas Pharma US Inc | 12 | $257 |
| Otsuka America Pharmaceutical, Inc. | 5 | $255 |
| Evoke Pharma, Inc. | 2 | $250 |
| Gilead | 2 | $250 |
| Phathom Pharmaceuticals, Inc. | 2 | $244 |
| Neurocrine Biosciences, Inc. | 2 | $240 |
| Abbott | 4 | $194 |
| Pfizer | 5 | $193 |
| Kowa Pharmaceuticals America, Inc. | 9 | $172 |
| Globus Medical | 1 | $171 |
| Recor Medical Inc | 1 | $147 |
| Ferring Pharmaceuticals Inc. | 1 | $129 |
| Shionogi Inc | 1 | $125 |
| Urovant Sciences Inc | 1 | $125 |
| Actelion Pharmaceuticals US, Inc. | 1 | $125 |
| Insmed, Inc. | 1 | $125 |
| Mannkind Corporation | 1 | $124 |
| Ardelyx, Inc. | 1 | $122 |
| Boehringer Ingelheim | 5 | $92 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $78 |
| Sunovion Pharmaceuticals Inc. | 2 | $61 |
| Exelixis Inc. | 1 | $48 |
| Novartis | 3 | $48 |
| Exact Sciences | 3 | $46 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$54,045 in reported general payments places this provider in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 69 | $91,760 |
| FarxigaDapagliflozin Propanediol | 74 | $88,583 |
| EliquisApixaban | 122 | $83,726 |
| IngrezzaValbenazine Tosylate | 22 | $81,718 |
| OzempicSemaglutide | 48 | $71,372 |
| JardianceEmpagliflozin | 46 | $60,741 |
| TrulicityDulaglutide | 26 | $37,372 |
| XareltoRivaroxaban | 54 | $33,080 |
| LinzessLinaclotide | 38 | $31,912 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 18 | $22,022 |
| JanumetSitagliptin Phos/Metformin Hcl | 17 | $18,595 |
| JanuviaSitagliptin Phosphate | 37 | $16,920 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $16,767 |
| Xigduo XrDapaglifloz Propaned/Metformin | 19 | $16,719 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $16,271 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,489 | $129,13295 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $5,002 | $105,35089 claims |
| PfizerEliquis | $193 | $83,726122 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $240 | $81,71822 claims |
| Novo NordiskOzempic | $730 | $71,37248 claims |
| Boehringer IngelheimJardiance | $92 | $60,74146 claims |
| MerckJanumet, Januvia | $681 | $35,51654 claims |
| Johnson & JohnsonXarelto | $412 | $33,08054 claims |
| AbbVieLinzess | $506 | $31,91238 claims |
| GSKTrelegy Ellipta | $33,946 | $22,02218 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,293 | $16,27115 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $255 | $12,14318 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Wendell WallShreveport$25K
- Bharat SachdevaShreveport$24K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- Paul RushingShreveport$13K
- Allan Matriano-LimShreveport$12K
- Scott McRightShreveport$12K
- Furqan AkhtarShreveport$11K
- Roan FlennikenShreveport$11K
- Donna RyanBaton Rouge$991K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.